Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
VolitionRx Limited (NYSE: VNRX) Just Landed On Our Watchlist
This Morning — Thursday, July 30, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get VNRX On Your Radar While It’s Still Early… July 30, 2026 Dear Reader, You have about 90 minutes before the open. Spend a few of them here. VolitionRx Limited (NYSE American: VNRX) is topping our watchlist this morning—Thursday, July 30, 2026. Here is the reason that matters most. Sysmex Corporation has built diagnostics equipment since 1968. Its analyzers run in hospital labs across more than 190 countries and regions. On June 17, 2026, it signed a collaboration agreement with Volition, a company carrying a market value near $7Mn. Read that again. A global manufacturer signed with a $7Mn company. Agreements rarely run that way. Sysmex has its pick of partners. It committed engineering time here for one reason: the Nu.Q NETs H3.1 assay had already been transferred onto the Sysmex platform successfully. Volition's whole plan is to license its assays to partners who already own the analyzers and the hospital relationships. Before June 17, that plan lived on a slide. It is now signed with one of the largest in vitro diagnostics manufacturers in the world. 
But keep in mind, VNRX has less than 7M shares listed as available to the public right now. When companies have small floats like this, the potential exists for big swings if demand starts to change. At the same time, VNRX appears to be flying under the radar while it’s currently trending below $1, according to Barchart. That has pushed the near-term momentum readings into rare territory. Barchart currently shows the Relative Strength Index on VNRX at 15.49 on a 9-day basis, 21.92 on 14-day, and 26.61 on 20-day. Anything under 30 is what most technical readers would call oversold territory, a condition some frameworks associate with the setup for a potential trend reversal. Several analysts have taken notice. Maxim Group analyst Michael Okunewitch reiterated a bullish rating on VNRX on July 24 with a $4 target. And according to TipRanks, Justin Walsh at Jones raised his target on VNRX from $3 to $24 in May, a level that sits well above its recent sub-$1 range. 
Revenue has also begun moving in the right direction. Volition reported first-quarter 2026 revenue of approximately $1Mn, representing a 300% increase from the same period last year. And Sysmex was not the only signed development to land on this name over the past few weeks. The July news added a second clinical leg. On July 7, 2026, Volition released real-world data showing its Nu.Q Cancer assay carried prognostic value in newly diagnosed lung cancer patients, work produced alongside clinicians at Hospices Civils de Lyon. Clinical certification of the test at that hospital system is complete, and the company is preparing a reimbursement submission in France with routine clinical use targeted before year end. Before we walk through the recent milestones, here is the foundation readers need first. Company Overview
VolitionRx Limited is a multi-national epigenetics company developing blood-based tests for the detection and monitoring of cancer and of diseases associated with NETosis, including sepsis. Research and development is centered in Belgium, with an innovation laboratory and office in the United States and an office in London. The company is headquartered in Henderson, Nevada and employs roughly 67 people. Everything the company sells is built on a single proprietary platform called Nucleosomics, which measures nucleosomes and their epigenetic modifications circulating in blood. From that one core, Volition has built four commercial pillars, each addressing a different clinical problem without requiring four separate research programs. Nu.Q Vet is the furthest along commercially. The canine cancer test is already available in more than 20 countries. A feline version aimed at lymphoma, the most common cancer in cats, has been submitted for peer review after detecting 86% of feline lymphomas at 97% specificity. Publication is expected to unlock a $5Mn contractual milestone payment, and management believes a feline test could roughly double its addressable market in companion animal health. Nu.Q NETs is CE-marked and clinically available across Europe, addressing an estimated $3.8Bn market. Nu.Q Cancer is moving toward routine clinical use in lung cancer in France. Capture-Seq is the earliest-stage and by far the largest pillar, a liquid biopsy method the company estimates addresses roughly $23Bn on an annualized basis. Revenue today comes from assay sales, research services through Nu.Q Discover, contractual milestone payments, and non-dilutive funding from Walloon Region agencies in Belgium. The licensing model is where management expects the step change: upfront payments, milestones, and royalties from large diagnostics groups. The company has confirmed active discussions with more than a dozen of the world’s leading diagnostics and liquid biopsy companies, several already at the technical evaluation stage. Market Sector Liquid biopsy is one of the few corners of diagnostics where the clinical need and the reimbursement path are moving at the same time. The economics are simple enough to state in a sentence: a blood draw that identifies disease earlier costs a fraction of the imaging, biopsy, and late-stage treatment it displaces. What has held the field back is not the science but the cost and complexity of the assays themselves. Sequencing-based approaches remain expensive enough that broad screening is difficult to justify outside high-risk groups. Volition’s position inside that sector is unusual in two respects. The first is that it is platform-based rather than indication-based. Most diagnostics companies of this size are built around one test for one disease, which means one regulatory path and one point of failure. Volition’s nucleosome chemistry supports cancer detection, sepsis triage, chronic inflammatory disease monitoring, and veterinary oncology from the same underlying science. That gives VNRX several independent paths forward on a single research budget. The second is that it is deliberately capital-light on the commercial side. The company estimates combined addressable markets above $27Bn across its pillars. The sepsis side deserves separate attention. Published estimates put global sepsis cases near 166M annually, with all-cause sepsis-related deaths representing 31.5% of total global deaths in 2021. Volition’s Nu.Q NETs assay is already included in DETECSEPS, a government-backed program in France valued at roughly $7.3Mn and scheduled to begin in the third quarter of 2026. The Run Of News Behind Our Coverage On (VNRX) July 7, 2026 – Volition released clinical data showing the prognostic value of its Nu.Q Cancer assay in newly diagnosed lung cancer patients, produced with researchers at Hospices Civils de Lyon, France’s second largest university hospital system. Clinical certification of the test at HCL is complete and a reimbursement submission in France is being prepared. June 17, 2026 – The company announced its collaboration with Sysmex (TYO: 6869) to optimize the Nu.Q NETs H3.1 assay on the Sysmex platform, following successful transfer of the assay onto that system. June 3, 2026 – Volition filed a new patent application covering use of its Nu.Q NETs test for triage and treatment monitoring in outbreak settings, and stated it is seeking strategic partners to deploy the platform in affected regions. May 27, 2026 – A consolidated corporate update detailed 300% first quarter revenue growth, progress toward the $5Mn veterinary milestone, inclusion of Nu.Q NETs in the DETECSEPS program, and active licensing discussions with more than a dozen global diagnostics leaders. May 6, 2026 – The company submitted for peer review a clinical manuscript reporting the accuracy of its Nu.Q Vet feline prototype assay in detecting lymphoma in cats, publication of which is expected to unlock a $5Mn contractual milestone payment. April 29, 2026 – Volition reported successful detection of nucleosomes in capillary blood from critically ill sepsis patients using a lateral flow prototype, a finger-prick format that could extend testing to the bedside, the emergency room, and eventually the home. 
7 Reasons Why VNRX Is Topping Our Watchlist This Morning—Thursday, July 30, 2026… 1. Global Validation: VNRX secured a collaboration with Sysmex, one of the world's largest diagnostics manufacturers, following the successful transfer of its Nu.Q NETs H3.1 assay onto the Sysmex platform. 2. Small Float: With fewer than 7M shares listed as available to the public, VNRX’s small float could have the potential to witness big swings if demand begins to shift. 3. Recent Developments: VNRX has delivered a steady stream of developments in recent months, including a Sysmex collaboration, new clinical data, patent activity, and continued commercial progress. 4. Analyst Coverage: VNRX continues to receive bullish analyst coverage, including a $4 target from Maxim Group and a $24 target from Jones analyst Justin Walsh, according to TipRanks. 5. Revenue Growth: VNRX reported first-quarter 2026 revenue of approximately $1M, representing a 300% increase from the same period last year. 6. Platform Diversity: VNRX has built four commercial programs from its proprietary Nucleosomics platform, spanning cancer, sepsis, veterinary diagnostics, and liquid biopsy applications. 7. Clinical Momentum: VNRX recently reported new lung cancer data, completed clinical certification at a major French hospital system, and is preparing a reimbursement submission in France with routine clinical use targeted before year end. Get VNRX On Your Radar While It’s Still Early…
Step back from the daily noise, and the picture on VNRX is straightforward. With fewer than 7M shares in its float, a market value under $10M, a new Sysmex collaboration, triple-digit revenue growth, and a potential $5M contractual payment tied to a manuscript already under peer review, VNRX has several developments worth watching. Nothing is guaranteed. Peer review can take time, licensing discussions may stall, and the company’s financial position should be reviewed directly in its filings. Still, whether your focus is emerging healthcare names, small-float setups, or licensing-driven companies, VNRX deserves a place on the screen. We’re already watching VNRX this morning. Take a look while it’s still early, and keep an eye out for my next update. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends |
0 التعليقات:
إرسال تعليق